15 APIs of interest in COVID-19 treatment
Recently, there have been many reports of investigations into the repurposing of currently available drugs as potentially effective treatments for the novel coronavirus disease COVID-19, with numerous clinical trials taking place.
To support these efforts, we have collected all approved API entries from Pharmaceutical Substances that have been considered in this context, and we would like to share these with you as freely available pdfs. This information includes established synthetic routes that are applied in industry for the preparation of these compounds.
Approved APIs investigated as potential COVID-19 treatments
- Azithromycin
- Baricitinib
- Camostat
- Chloroquine
- Cobicistat
- Darunavir
- Favipiravir
- Fingolimod
- Hydroxychloroquine
- Lopinavir
- Ritonavir
- Remdesivir
- Ruxolitinib
- Thalidomide
- Tofacitinib
Or access all APIs in the full PDF
Sign up for a free trial to find further API Syntheses, including the recently discussed Dexamethasone in Pharmaceutical Substances.
About Pharmaceutical Substances
Pharmaceutical Substances is designed to be a complete reference guide to every pharmaceutical compound of significance. It provides access to syntheses, patents and applications for a compendium of over 2,700 active pharmaceutical ingredients (API's) of interest to the chemical and pharmaceutical industries. For more information click here.
Your institutional trial
To get permanent access to Pharmaceutical Substances please request a trial for your institution.
Contact
Thieme Chemistry Marketing Phone:+49-711-89310 E-Mail